This review describes the pathogenesis and significance of chemically-induced hepatocellular altered foci in rat liver. The measurement of induction of foci can bc used for carcinogen detection and the measurement of the modulation of foci by chemicals other than the inducing agent identifies enhancers or inhibitors of liver carcinogenesis.
INTRODUCTION
The experimental induction of liver cancer in rodents is characterized by the development of several distinct cellular lesions prior to the appearance of malignant neoplasms. Among the lesions that have been postulated to be precursors of hepatocellular cancer are oval cell proliferation (13, 28) altered (hyperplastic) foci (2, 15, 59, 79) and hyperplastic (neoplastic) nodules (1 5,59,79) . The nature of these lesions in various species has been previously reviewed (1 05). This paper deals with chemically-induced hepatocellular altered foci in rats and their utilization in detection of carcinogens and modifiers of carcinogenesis.
The hepatocellular altered focus is the earliestappearing distinct lesion of hepatocytes induced by liver carcinogens. The focus is smaller than a lobule and is composed of cells with abnorpal staining properties and a variety of phenotypic abnormalities (89, 105) . The cells of a focus are usually organized in plates which merge with those of the surrounding normal parenchyma. Ultrastructural studies have revealed distinct hepatocellular characteristics of focus cells (26, 93).
SIGNIL~CANCE OF ALTERED FOCI
In the livers of older rats, cryptogenic foci can be morphologically and phenotypically similar to contents whereas hyperbasophilic foci had an aneuploid DNA content like carcinomas (54). It is possible, therefore, that eosinophilic foci may develop into nodules and basophilic foci into carcinomas. Studies of transplantation of foci have not revealed progressive growth (56), and, thus, there is no evidence that foci are neoplastic.
The nature of endogenous factors underlying the progression of foci is presently unknown. There is evidence that administered bile acids enhance development of foci (7), but the role of endogenous bile acids has not been established. Gonadectomy did not have a substantial effect on foci development (33), suggesting that normal levels of gonadal hormones are not determinative, although exogenous hormones certainly can exert an effect (1 14) .
The development of carcinomas from foci may require further genetic alterations in the cells of foci (102, 105) . Evidence has been provided that cells in rat liver foci have a lesser DNA repair capacity than normal cells (57). This could make them more susceptible to genetic alteration during continued carcinogen exposure, even though they are less susceptible to toxic effects of activation-dependent carcinogens (1 1 l), as discussed in the next section of this paper.
Clearly, only a small fraction of foci develop into neoplasms, inasmuch as foci greatly outnumber neoplasms (75, 79, 80, 108, 11 1). Estimates of the rate of progression are in the order of 1 in 1,000 (97) to 1 in 2,500 (70) . Probably, different types of foci have different potentials for developing into neoplasms (24, 54) .
The demonstration that the progression of foci to neoplasm formation is enhanced by promoters (35, 70, 97) provided strong evidence that foci are a source of neoplasms. Nevertheless, observations that they can remain dormant or even undergo phenotypic reversion indicates that they are not committed to neoplastic development, but may be truly preneoplastic.
It is, of course, quite likely that there are several possible pathways for the development of liver cancer. One ofthex appears to involve the altered focus as a significant "preneoplastic" population. This paper describes studies on the characteristics of foci and the quantitation of foci to monitor effects of chemicals on liver carcinogentsis.
CHARACI-ERISTICS OF CHEMICALLY-INDUCED

ALTERED FOCI
Based upon abnormalities in the conventional staining properties of the a l l s in rat liver foci, they can be classified as eosinophilic, basophilic, clear, or mixed types (89). A variety of other phenotypic abnormalities have been identified in altered foci (Table I ). The number of abnormalities varies between different histological types of foci and even among foci of each type.
Enzyme Histochemical Abnormalities
Foci in rats have been demonstrated to display a variety of enzyme abnormalities such as reduced activity of glucose-6-phosphatase (G-6-Pax) (2,2 1) and adenosine triphosphatase (ATPase) (34,75,80) and reappearance of gamma-glutamyl transferase (GGT) activity (22, 32). Also, the appearance of abnormal enzymes such as aldehyde dehydrogenase (30) and a placental form of glutathione transferase (38) has been described. All these properties are generally uniform in their expression within a single focus, but distinctly heterogeneous between foci (25, 34, 70, 73).
GGT activity and ATPase deficiency appear to be quite stable in foci following cessation of carcinogen exposure. However, care is required in the use of GGT as a marker because activity can be induced in penportal hepatocytes by drug-metabolism enzyme inducing xenobiotics (1 6). and activity is elevated in aged rats (36).
Other Biochemical Abnormalities
Glycogen Storage. Bannasch (2) first reported that nitrosamine-induced foci displayed excessive storage of glycogen. Subsequently, glycogen-storing foci were demonstrated with other types of carcinogens (1 00). This abnormality appears to be related at least in part to a deficiency of G-6-Pase in foci cells.
Fibronectin. Fibronectin is high molecular weight glycoprotein that is present on the surface of many types of cells including hepatocytcs. Some foci have been found to display reduced amounts of fibronectin (47, 83). and associates (97, 100, 110) . The basis for this is unknown. Femtin is actually increased in the cells of foci and thus, lack of iron storage may be due to abnormal femtin or femtin function. Under some conditions, expression of IS-is dependent upon continued carcinogen exposure; after cessation of exposure a phenotypic reversion of this property can occur whereby the cells in foci reacquire the ability to store cellular iron (1 9, 97).
As a marker, IS-has a number of advantages. It is applicable to all species studied thus far (103) . Also, the ability to distinguish between iron-excluding and iron-engorged cells at the ultrastructural level has facilitated reliable electronmicroscopic studies of ultrastructural abnormalities in altered foci (26, 93). IS-is the only marker that results in a difference in the density of altered cells rendering them separable on density gradients (55).
Resistance to Cytotoxicity. The resistance of neoplastic cells to the cytotoxic effects of carcinogens has long been known (14). Resistance to cytotoxicity was demonstrated by Farber and co-workers in altered foci (1 l l) and nodules (14) . The resistance appears to result largely from reduced xenobiotic activation and enhanced detoxification systems (1, 31, 37, 40, 62) . In normal liver cells with greater activation of carcinogens, an antimitotic effect is exerted as a consequence of toxicity and hepatocytes are thereby impaired in responding to a mitogenic stimulus. In contrast, proliferation occurs in altered foci and nodules. With the use of partial hepatectomy to stimulate proliferation in conjunction with a cytotoxin, foci can be rendered highly conspicuous for easy detection in the bioassay of carcinogens (14).
INDUCTION OF ALTERED FOCI AS A MEANS OF
DETECTINO DNA-REACTIVE CARCINOGENS In light of the evidence that chemically-induced foci are precursors of liver neoplasms, and because foci are induced in the livers of several species by carcinogens, the induction of foci has been proposed as one type of limited bioassay for detecting carcinogens (65, 99, 103) . Carcinogens are defined operationally by the production of neoplasms after chronic administration. Some carcinogens are DNAreactive and consequently capable of inducing neoplastic conversion whereas others are not DNA-reactive, but exert effects on neoplastic development that result in enhanced tumor formation. These 2 types of agents have been designated as genotoxic and epigentic carcinogens, respectively, in the classification of carcinogens developed by Williams and Weisburger (1 09). Different approaches are required for the detection of genotoxic or DNA-reactive carcinogens and epigenetic carcinogens. The rapid induction of foci is an action of DNAreactive hepatocarcinogens, occasionally resulting from even a single exposure, but usually occumng in less than 12 weeks and increasing with continued administration. Therefore, examination of the liver for foci at 6-18 weeks of continued or repeated administration of a test compound at a maximally tolerated dose is a reasonable limited bioassay. In fact, even carcinogens that may be only weakly or indirectly genotoxic, such as methapyrilene, can be detected by this approach (1 8).
In assaying for foci induction, some investigators have advocated the use of only a single exposure, usually in conjunction with phenobarbital (65) or some other form of enhancement such as partial hepatectomy (69) or feeding of a choline-deficient diet (84). The rapid induction of"nodu1es" has been described using partial hepatectomy combined with administration of 2-acetylaminofluorene (9 1, 94). Such complex procedures have not been shown to be essential for the detection of any carcinogen and entail a number of problems. Although such procedures may enhance the development of carcinogen-induced lesions, chemicals that are positive under conditions of combined exposures or treatments can only be regarded as suspect carcinogens, since carcinogens are defined by their effects in the absence of deliberate exposure to any other agent. On the other hand, negative results in such assays are of very limited value because measurement of induction of lesions with a single or few exposures may simply lack sufficient sensitivity, as shown in a recent application of one such approach (50). In contrast, continuous administration either in feed, by gavage, or by injection for at least 18 weeks provides a more rigorous and interpretable assay for carcinogenicity. This can be followed by a promoting agent such as phenobarbital to enhance the sensitivity further. During the induction or enhancement phases, the development of liver lesions can be monitored by following blood GGT levels (78).
A final point about procedures using partial hepatectomy is that they require unnecessary mutilation of animals.
The protocol used for limited bioassay in this laboratory is depicted in Fig. 1 , Some of the agents that have been tested under approximately these conditions are listed in Table 11 . Chemicals that were negative in assays using single or limited exposures are not tabulated, since these results are not of great strength for the reasons indicated above. It is evident from the results in Table I1 that a wide variety of structurally different carcinogens can be identified by the production ofaltered liver foci during limited exposure.
ENHANCEMENT OF ALTERED FOCI AS A
MEANS OF IDENTIFYING POTENTIAL
NEOPLASM-PROMOTING AGENTS
The basis for an approach to the rapid detection of liver neoplasm promoters was provided by the demonstration that the liver neoplasm promoter phenobarbital enhanced the persistence and pro-gression of altered foci in rat liver (35, 70, 108). In the subsequent applications of this phenomenon, the general approach has been to administer a genotoxic hepatocarcinogen first and then to give the test agent to determine if it has an enhancing effect upon the number or size of foci (103) . Studies have also been made of increased DNA synthesis in foci (8 1).
Enhancement of foci by an agent given after a genotoxic liver carcinogen can also occur through a summation effect, when the second agent is also a genotoxic carcinogen (1 12). Therefore, in studying the enhancement of foci as evidence of neoplasm promotion, it is essential that the test agent first should be demonstrated to be nongenotoxic and then in the in vivo studies, to produce an enhancement only when given after and not before a DNA-reactive carcinogen. Thus far, only phenobarbital has been shown to fulfill these requirements (82, 106). Unfortunately, enhancement of foci by genotoxic agents administered aAer a carcinogen is sometimes uncritically reported as promotion (77,86).
An important extension of these concepts is that the absence of an enhancing effect of a compound administered after a genotoxic carcinogen indicates an absence of summation and, therefore, provides evidence of a lack of genotoxicity of the test chemical (104). In assessment ofenhancement ofcarcinogenesis, the general approach of administering a DNA-reactive carcinogen followed by a second agent has many variations (43,103). Some involve a powerful initial carcinogenic exposure, such as diethylnitrosamine plus partial hepatectomy, while others involve intense combination effects such as the feeding of 2-acetylaminofluorene coupled with partial hepatectomy. The model used in this laboratory ( Fig. 2 ) differs from these in several respects. In this model, a DNA-reactive carcinogen, usually 2-acetylaminofluorene or diethylnitrosamine, is administered either orally or by injection in the first phase for 8-1 2 weeks. This results in the gradual induction of foci such that at the time of administration of the second agent, after an interval of cessation of exposure of 2 4 weeks, foci are already present. The main purpose of this approach is to distinguish promotion from cocarcinogenic effects. Promotion, by definition (4), involves facilitation of the growth of neoplastic cells. By first inducing detectable foci, the effect of the second agent on a carcinogen-altered population, which probably includes neoplastic cells (see previous discussion), is demonstrated. In regimens where a carcinogen is followed shortly by a second agent, before foci appear, enhancement can be due to increased neoplastic conversion of carcinogen-damaged cells, which is really a cocarcinogenic effect (104). It is also for this reason that an interval of 2-4 weeks is allowed between administration of the initiating carcinogen and commencement of exposure to the second agent. Other reasons for the protracted initiation phase are to standardize a model for the reliable detection of DNA-reactive carcinogens (see previous discussion) and to have a model in which the sequence of administration of 2 agents can meaningfully be reversed in order to prove that any enhancement by a second agent truly represents promotion and not syncarcinogenesis.
A wide spectrum of agents has been tested for enhancement of foci in the various models in use (Table 111) . Most of these studies have used male animals, but there is evidence that for some agents liver promotion may be more effective in females (1 1). Also, it is noteworthy that phenobarbital and DDT, which are strong promoters of rat liver carcinogenesis, have been inactive in the hamster (88, 90).
The enhancement of foci by a nongenotoxic agent when given after, but not before a genotoxic carcinogen demonstrates a promoting action. Nevertheless, many and perhaps all "promoters" can increase the incidence of neoplasms under conditions of chronic exposure (109) . In the liver, this effect is probably the result of the promotion of pre-existing transformed cells (101, 102) , which are otherwise manifested by the development of cryptogenic altered foci and neoplasms in untreated animals. Regardless, by the operational definition of carcinogenesis, production of neoplasms establishes a compound as a carcinogen. For this reason, in the classification of carcinogens by Williams and Weisburger (log), promoters are designated as a class of epigenetic carcinogens lacking the ability to react with and damage DNA. Therefore, the demonstration ofpromoting action may be regarded as a means of distinguishing oncogenic agents with this property from genotoxic carcinogens. Also, a positive result for promotion indicates that the chemical is a potential carcinogen. 
INHIBITION OF ALTERED FOCI AS A MEANS OF
It is well established that chemicals with the property of modifying biotransformation processes in the liver are capable of inhibiting the liver carcinogenicity of carcinogens that are bioactivated in the liver (98, 104). A logical extension of this knowledge is that such inhibitors should reduce the induction of foci by activation-dependent carcinogens. Indeed, this is the case, as shown in Table IV .
Several chemicals given after liver carcinogens, however, also have been reported to inhibit foci (Table IV) . Foci are known to undergo phenotypic reversion (see previous discussion) and it is possible that xenobiotics could facilitate this. However, in these studies, GGT was used as the marker for foci, and in light of the finding that nafenopin inhibits GGT activity (1 7,60), it may be that the foci simply were made undetectable by the GGT reaction.
CONCLUSIONS
Liver altered foci have been established to be an abnormal population of cells derived from hepatocytes that can be produced by liver carcinogens in mice, rats, hamsters, and monkeys. They appear to be precursors of both benign adenomas and carcinomas. In particular, hyperbasophilic foci may be related to carcinomas. Similar lesions have been reported in humans (27) and may be the precursors of hepatocellular carcinomas.
IDENTIFYING ANTICARCINOGENS
The rapid induction of foci in experimental animals can be used to identify DNA-reactive carcinogens. Also, the enhancement of foci induced by a non-genotoxic agent can be used to identify promoters and the inhibition of induction of foci can serve to reveal anticarcinogens.
ACKNOWLEDGMENTS
The author thanks his many co-workers, who are evident from the reference list, for their valuable collaboration. This paper was prepared by Jeffrey Williams and Regina Boscia. 
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
cell stage in rat liver carcinogenesis. A quantitative approach. Biochim. Biophys. Acta 605: 247-304. Farber E (1 956). Similarities in the sequence ofearly histologic changes induced in the liver of the rat by ethionine, 2-acetylaminofluorene, and 3'-methyl4dimethylaminoazobenzene. Cancer Res. 16: 142-148. Resistance to iron accumulation and presence of hepatitis B surface antigen in preneoplastic and neoplastic lesions in human hemochromatotic liven. Hepatogastroenterology 29: 49-5 1.
28. Inaoka Y (1967 
DISCUSSION
Dr. Bannasch. Did you try to correlate the decrease in fibronectin with any of the phenotypes seen in your H&E sections?
Dr. Williams . We did document that the foci that showed the decreased fibronectin were identifiable by other phenotypic markers, but there was no correlation. For example, some GGT-positive foci displayed decreased fibronectin where others were fibronectin positive.
Dr. Ifo. Did you study only the ras oncogene or did you look into other oncogenes? I am asking this because, in our department, we have undertaken many studies on the ras oncogene. However, with our data, we have not found good correlation such as you have reported.
Dr. Williams. Were they studied by immunohistochemical stains of the p-2 1 protein?
Dr. Ito. Yes, p-21.
Dr. Williams.
We have looked at one other, the c-myc, which did not show the same level of expression as the p-21 in the same liver tumors in serial sections.
Dr. Popp. Gary, have you tried to correlate the staining with the p-2 1 to cell replication rates within lesions?
Dr. Williams. No. Dr. Ray Yang. Mr. Chairman, could I ask a general question, not only to Dr. Williams, but also to Drs. It0 and Maronpot, and everyone here, in fact? Earlier this afternoon, Dr. Ito's lecture was very impressive, not only in terms of the number of chemicals (146), the short-term time interval (8 weeks), involved but also the number of parameters he looked at (10-12 applications of chemicals), and so on. One cannot help but reach the conclusion after hearing his presentation that, as far as liver cancer is concerned, we can forget about the longterm bioassay. Then, Dr. Maronpot summarized the NTP effort through Dr. Pitot's and Dr. Peraino's laboratories and the result is not clear-cut, One out of 4 is not a terrifically good correlation, even 3 out of 4. Then, at the end of Dr. Maronpot's talk, Dr. Williams specifically mentioned the order of the DEN treatment and that partial hepatectomy may influence the outcome. My question is: are the variations between the 2 studies the result of factors such as the order of application? As I recall, Dr. It0 applied DEN first, followed by partial hepatectomy, whereas in the NTP sponsored study, it was the reverse. Another very obvious difference is the time, 8 weeks versus 42 or 60 weeks. Or is it simply a sampling problem because the NTP did not study high enough numbers? Finally, could it be possible that colleagues on the other side of the Pacific do better work than we do?
Dr. Maronpot. I have a partial answer, but I am going to let Dr. Pitot answer first.
Dr. Pitot. There was one difference that was not mentioned and that was the dose. The dose of initiating agent in Dr. Ito's system is 10-fold higher than the dose that we use. The dose that Dr. Williams uses, as well as that of Dr. Bannasch's group, is similarly higher when given as a single shot or by multiple doses. That is one major difference in the systems. Another major difference is seen in the results of chromosomal studies on cells of altered hepatic foci. Dr. Williams described gross chromosomal abnormalities in livers of rats following AAF treatment, In a recently published paper (Carcinogenesis 10: 387, 1989), we demonstrated that in Peraino's system, when a low dose of an initiating agent is given and then a promoting agent, the isolated focal cells have perfectly normal karyotypes. Dr. Seglen in Norway, who also worked with Dr. Farber, showed that the neoplastic nodules themselves are predominantly diploid. Dr. H. Rabes, using techniques similar to those employed by Dr. Williams, also showed that focal hepatic lesions were either diploid, tetraploid or a mixture of the 2. Thus, one cannot state that all focal hepatic lesions have gross chromosomal or DNA abnormalities. In certain systems they may, but in others they may not.
With respect to proto-oncogene expression, we have reproduced some of the sort of findings that you reported, but to do so we must give not only diethylnitrosamine but a second dose of an alkylating carcinogen aAer many foci have already developed. One may then observe foci, both by themselves and within other focal lesions, that express higher levels of some proto-oncogenes. If one looks just in the low-dose regimen, that is low-dose DEN followed by PH, then one sees predominantly either no change as compared to the extremely low level in the normal liver, or, in fact, a lower level of expression. Again, it is important, as the last questioner here emphasized, to consider the difference in the systems being studied and the questions being asked.
Dr. Williams. I have previously pointed out differences between your findings and ours. You have reported that there was no phenotypic reversion under your conditions whereas in the systems that Dr. Schulte-Hermann and I use, that feature for some reason, occurs more frequently. However, just to confirm what you said, the dose makes a difference, the carcinogen makes a difference, the strain of an-imals makes a difference, the age makes a difference, and whether or not a partial hepatectomy is performed makes a difference-these are all important factors.
Dr. Maronpot. I think you might have got a bit of an answer there, Ray; I hope so. I would like to make a comment and provoke a response. The data you presented at the end ofyour comments in which you indicated that you would throw out for the audience to react to, I would like to react to. This relates to the focus type classification that you used and the categorization of cryptogenic neoplasms in the Fischer 344 rat. These data are so divergent from what we have found and what was presented earlier and the numbers of animals examined are so small that I cannot help but question whether data should be presented that are so scanty, because it might be misleading.
Dr. Williams. As I pointed out, we did those experiments specifically because we were aware of what Dr. Harada was showing and we were interested in how that related to the animals that we had treated at our institute.
Dr. Stitzel. What diet do you have your animals on at your institute?
Dr. Williams. The NIH-07.
Dr. Mahon.
Returning to what you and Professor Schulte-Hermann have been speaking about, I had the impression that, within initiated cells, there is a whole spectrum of different initiated types, each of which has the potential for another spectrum of responses in promotion. This tells me that at no point can I identify exactly what protocol I should use for any given chemical.
Dr. Williams. What is the information that you are seeking when you say you cannot decide what protocol to use?
Dr. Mahon. People here are talking about using these techniques or data instead of performing chronic studies to identify carcinogens. If I am not doing research, but if I am trying to find out whether or not I actually have a carcinogen, what model should be used instead of performing chronic studies?
Dr. Williams. I will stand by my assertion that a chemical that rapidly induces foci as characterized by the usual markers would be carcinogenic to the liver in a chronic study at the MTD. Returning to an earlier question about different protocols, the only meaningful results are the positive ones because there are deficiencies in all study designs which can account for negative results.
Dr. McConnell. But, haven't you designed your studies to make them show a high degree of correlation if you only look for positive correlations? Don't you fall into a trap similar to that experienced by the in vifro mutagenesis people by only looking for positive correlations and not looking for the negative correlations with data from non-carcinogens? I was particularly impressed with Dr. Ito's work, where he also looked at non-carcinogens. Do we not have to look at both sides of the equation before we can truly prove correlation? Dr. William. I think we are past the era of correlations. Now we know that there are a variety of mechanisms of action of carcinogens and that it is not possible to detect all carcinogens in in vifro, short-term tests. Nevertheless, intelligently used, such tests pick up a very significant number of carcinogens. Now, what that allows you to do is to eliminate those chemicals from chronic bioassays. If you go the further step of the limited in vivo bioassay, then you pick up additional chemicals that do not need to go to chronic bioassay. At the end, the chemicals left would be those such as peroxisome proliferators or others that would not show up in these short-term assays. Then, when you do a bioassay, you can do it under much more meaningful conditions than just the MTD and a half MTD.
Dr. Vesselinovitch. Gary, would you not see an increase in eosinophilic foci with some peroxisome proliferators that are not necessarily carcinogens at the MTD, after 3 months?
Dr. William. I have not studied any peroxisome proliferators that are not liver carcinogens. I do not know; has somebody else? [No reply.] I would say that if an agent is shown to be a peroxisome proliferator, the chances that it behaves as a liver carcinogen at 2 yr would be loo%, based on what we know today. I think Rolf would probably say about the same thing concerning increases in liver DNA and liver weight; these are very good predictors of the eventual outcome.
Dr. McConnell. In your first slide, you indicated you felt that the progression in the steps to neoplasia possibly goes from foci to carcinoma. Do you consider a neoplastic nodule to be an end-stage lesion then?
Dr. Williams. In our studies, it has been mostly an end-stage phenomenon. I know that some investigators regard nodules as the obligatory precursor for carcinomas. This is tied in with the concept of progression. The differences may, as Dr. Pitot pointed out, relate to the conditions that we are studying.
